Effect of Early Memantine Administration on Outcome of Patients With Moderate to Severe Traumatic Brain Injury

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05531383

Enrollment

Registered

2022-09-08

Start date

2021-11-26

Completion date

2024-07-09

Last updated

2022-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic Brain Injury

Brief summary

Effect of Early Memantine Administration on Outcome of Participents with Moderate to Severe Traumatic Brain Injury

Detailed description

Studying the effect of memantine on platelet, platelet/lymphocyte ratio (PLR) and C reactive protein (CRP) & serum NSE levels in participents with moderate to severe TBI as well as outcome. Investigators evaluate prognostic effect of memantine on participents with moderate to severe TBI. also to estimate which of platelet, platelet/lymphocyte ratio (PLR), C reactive protein (CRP) or serum NSE levels will be affected by administration of memantine in participents with moderate to severe TBI as a predictor of outcome.

Interventions

DRUGMemantine Hydrochloride

study the effect of memantine on platelet, platelet/lymphocyte ratio (PLR) and C reactive protein (CRP) & serum NSE levels in patients with moderate to severe TBI as well as their outcome.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Moderate to severe closed TBI with initial GCS of 4-12 * Age from 18 to 65 years of both sexes * Able to tolerate enteral feeding and drug administration within the first 24 hours of TBI.

Exclusion criteria

* Open TBI or patients who would need open craniotomy later on. * Comorbid illnesses, such as diabetes mellitus, ischemic heart disease, acute myocardial infarction within the past 48 hours, acute or chronic renal insufficiency, hepatic diseases, autoimmune abnormalities, history of epileptic fits and known malignancies. Patients with chest, cardiac, abdominal trauma or any other trauma requiring mechanical ventilation. Patients with body mass index (BMI) \<18.5 or \> 34.9 kg/m2.

Design outcomes

Primary

Measure	Time frame	Description
prognosis of moderate to sever head injury	7days	Evaluating the effect of memantine administration on the conscious level of patients using the Glasgow coma scale

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026